ArticleAdvances in therapy2026
Development and Content Evaluation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04881760 (A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
Who cites it
2 citing papers in PubMed.
- Understanding reasons for initiation and experience with tirzepatide among individuals with obesity or overweight: Results from the PERCEPTIONS survey.Obesity pillars · 2026Article
- Psychometric Validation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity or Overweight.Advances in therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionObesity management medications can reduce body weight and have an impact on patients' appetite and eating behaviors. Existing patient-reported outcome (PRO) measures do not fully capture appetite and eating behavior concepts relevant to individuals living with obesity, including those receiving treatment. Here we describe the development and content evaluation of the Eating Behavior and Appetite Questionnaire (EBAQ), a new PRO measure to enable a comprehensive assessment of appetite and eating behaviors which are important to individuals living with obesity.
methodsThe EBAQ was developed on the basis of findings from a targeted literature review, findings from exit interviews with participants (N = 40) in a phase 2 trial for retatrutide (NCT04881760), and interviews with clinicians specializing in obesity medicine (N = 3). Cognitive interviews were conducted with USA-based adults with obesity or with overweight and ≥ 1 obesity-related complications (hypertension, dyslipidemia, cardiovascular disease) (N = 24) to evaluate the content of the EBAQ.
resultsAll 24 cognitive interview participants reported a positive overall impression of the EBAQ and that they understood the instructions and recall period. Most participants (n = 23, 96%) found the response options to be clear and appropriate. Items in the EBAQ were considered clear and relevant by the participants. The 21-item EBAQ is a new PRO measure with three domains to evaluate eight appetite and eating behavior concepts relevant to obesity and which may change with obesity treatment.
conclusionThe EBAQ may be used in clinical trials, clinical practice, or observational research to evaluate the impact of obesity and the effect of obesity treatment on appetite and eating behaviors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.